BioCentury
DATA GRAPHICS | Product Development

On heels of Metsera, Lilly delivers more momentum for amylin in obesity

ADA data show 11.5% placebo-adjusted weight loss at 12 weeks for eloralintide 

June 16, 2025 10:05 PM UTC

ADA data from Eli Lilly this week further make amylin’s case as obesity’s hottest target. The impressive early data for Lilly’s amylin program show strong weight loss efficacy as monotherapy combined with a relatively benign safety profile.

The Phase I data from Eli Lilly and Co. (NYSE:LLY) were disclosed in an American Diabetes Association’s annual scientific sessions abstract for amylin receptor-biased agonist eloralintide. They come a week after Metsera Inc. (NASDAQ:MTSR) announced top-line Phase I data for its MET-233i that appeared to position the amylin agonist as a best-in-class molecule — and three months after two pharmas jumped into the amylin race via big partnerships...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Eli Lilly and Co.

Metsera Inc.